Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study

Cuisset, Thomas; Deharo, Pierre; Quilici, Jacques; W. Johnson, Thomas; Deffarges, S.; Bassez, Clémence; Bonnet, Guillaume; Fourcade, Laurent; Philippe Mouret, Jean; Lambert, M.; Verdier, Valentine; Morange, Pierre‐Emmanuel; Alessi, Marie‐Christine; Louis Bonnet, Jean

doi:10.1093/eurheartj/ehx175

Public

Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study

Published in European Heart Journal • Mar 21, 2017

Authors:

Thomas Cuisset

Pierre Deharo

Jacques Quilici

Abstract

AIMS: Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both drugs are associated with an increase in bleeding complications. The objective of the present study was to evaluate the benefit of swit...

Subject

Medicine

Prasugrel

Acute coronary syndrome

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!